Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Press Releases

3 Mar 2021

Lobe Sciences Appoints NFL Alumni Association President, Bart Oates Esq. to Advisory Board

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

3 Mar 2021

Pure Extracts Orders Over 30,000 Vape Cartridges in Preparation for Retail Distribution

VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp....

By Microdose

Press Releases

2 Mar 2021

PSYC Supports Launch of First Psychedelic Peer Support Program, Fireside Project, Through Sponsorship Commitment

PSYC to Contribute to First of Its Kind 24/7 Psychedelic Peer Support Hotline LAS VEGAS, NV, March 02, 2021 (GLOBE NEWSWIRE) — Global Trac Solutions, Inc....

By Microdose

Press Releases

2 Mar 2021

PsyBio Therapeutics Initiates Pilot Scale Development of Proprietary Biosynthetic Psilocybin with Global Contract Research, Development and Manufacturing Organization

OXFORD, Ohio and COCONUT CREEK, Fla....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

2 Mar 2021

Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in a Phase II Clinical Trial

London, United Kingdom-(Newsfile Corp....

By Microdose

Press Releases

2 Mar 2021

NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data

Vancouver, British Columbia–(Newsfile Corp....

By Microdose

Press Releases

2 Mar 2021

Psyched Wellness Provides Update on Pre-Clinical Trial of Its Muscimol Extract AME-1

Toronto, Ontario–(Newsfile Corp....

By Microdose

Press Releases

2 Mar 2021

PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.

TORONTO, March 01, 2021 (GLOBE NEWSWIRE) — PsyBio Therapeutics Corp....

By Microdose

Press Releases

1 Mar 2021

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

DENVER, March 01, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma company in the life sciences category committed...

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.